A. Huennemeyer

发表

Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects

G. Lahu, D. Bredenbröker, N. Nassr, 2011, Expert opinion on drug safety.

Effect of Steady‐State Enoxacin on Single‐Dose Pharmacokinetics of Roflumilast and Roflumilast N‐Oxide

M. Elmlinger, P. Ruth, M. Hinder, 2011, Journal of clinical pharmacology.

Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.

M. Elmlinger, R. Hermann, G. Lahu, 2009, International journal of clinical pharmacology and therapeutics.

Oral, Once-Daily Roflumilast and Its Active N-oxide Metabolite Exhibit Dose-Proportional Pharmacokinetics Between 250μg and 500μg

C. Gleiter, G. Boehmer, T. Bethke, 2004 .

Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.

K. Duffy, R. Hermann, O. von Richter, 2009, British journal of clinical pharmacology.

Effect of Single and Repeated Doses of Ketoconazole on the Pharmacokinetics of Roflumilast and Roflumilast N‐Oxide

R. Hermann, O. Richter, G. Lahu, 2008, Journal of clinical pharmacology.

CHRONOPHARMACOLOGY OF ROFLUMILAST: A COMPARATIVE PHARMACOKINETIC STUDY OF MORNING VERSUS EVENING ADMINISTRATION IN HEALTHY ADULTS

B. Lemmer, G. Lahu, T. Bethke, 2010, Chronobiology international.

Midazolam microdosing applied in early clinical development for drug–drug interaction assessment

G. Mikus, M. Goettel, S. Wiebe, 2020, British journal of clinical pharmacology.

Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity

M. Ingelman-Sundberg, R. Hermann, O. Richter, 2006, Clinical pharmacology and therapeutics.

Effect of Fluvoxamine on the Pharmacokinetics of Roflumilast and Roflumilast N-Oxide

R. Hermann, O. Richter, G. Lahu, 2007, Clinical pharmacokinetics.